J Korean Ophthalmol Soc.  2008 Jun;49(6):973-978. 10.3341/jkos.2008.49.6.973.

Clinical Analysis of Anisometropic Amblyopia with Monocular Vision 0.1 or Worse

• Choi MY
• Kim YH

• KMID: 2110879
• DOI: http://doi.org/10.3341/jkos.2008.49.6.973

Abstract

PURPOSE: To analyze the results of treatment in pure anisometrpic amblyopia with unilateral visual acuity of 0.1 or worse.
METHODS
The major eligibility criteria included pure anisometropic amblyopia with age <10 years, best-corrected visual acuity 0.1 or worse in the worse eye and 0.5 or better in the good eye after the wearing of optimal spectacle correction for a minimum of 4 weeks, and the minimum follow-up was 6 months. Twenty-one patients were selected and we analyzed the age at the amblyopia treatment, the type and degree of anisometropia, and the final visual acuity after treatment for visual improvement. Successful treatment was defined as a final visual acuity of 0.3 or more.
RESULTS
The mean age at treatment was 5.2 years. The types of anisometropia were hypermetropic in 14 patients, astigmatic in 4, and myopic in 3. The mean duration of treatment of amblyopia was 16 months, and 13 of 21 children with pure anisometropic amblyopia achieved 0.3 or better. The age at treatment was younger and the compliance rate was higher in the success group than in the failure group.
CONCLUSIONS
The most common type was hyperopic in the pure anisomteropic amblyopia. Compliance and age at treatment were significantly related to best visual acuity attained in pure anisometropic amblyopia with unilateral visual acuity of 0.1 or worse.

Keyword

Amblyopia; Anisometropia; Hyperopia; Patching therapy

MeSH Terms

Amblyopia
Anisometropia
Child
Compliance
Eye
Follow-Up Studies
Humans
Hyperopia
Vision, Monocular
Visual Acuity

Reference

References

1. Woodruff G, Hiscox F, Thompson JR, Smith LK. The presentation of children with amblyopia. Eye. 1994; 8:623–6.

2. Tomilla V, Takkanen A. Incidence of loss of vision in the healthy eye in amblyopia. Br J Ophthalmol. 1981; 65:575–7.

3. Rahi J, Logan S, Timms C. . Risk, causes, and outcomes of visual impairment after loss of vision in the non‐ amblyopic eye: a population‐ based study. Lancet. 2002; 360:597–602.

4. Stewart CE, Fielder AR, Stephens DA. . Treatment of unilateral amblyopia: influencing visual outcome. Invest Ophthalmol Vis Sci. 2005; 46:3152–60.

5. Park SB, Kwon JY. Occlusion effects on anisometropic amblyopia. J Korean Ophthalmol Soc. 2001; 42:1753–9.

6. Cho YA, Lim S. Treatment of high anisometropic amblyopia. J Korean Ophthalmol Soc. 1993; 34:661–6.

7. Oh DE, Lim KH. Efficacy of occlusion therapy in amblyopia: type, depth & timing of amblyopia. J Korean Ophthalmol Soc. 2003; 44:2850–6.

8. Repka MX, Ray JM. The efficacy of optical and pharmacological penalization. Ophthalmology. 1993; 100:769–75.

9. Dorey SE, Adams GG, Lee JP, Sloper JJ. Intensive occlusion therapy for amblyopia. Br J Ophthalmol. 2001; 85:310–3.

10. Kim IS, Cho YA. Therapy of strabismic amblyopia less than 0.1 vision. J Korean Ophthalmol Soc. 1995; 36:338–43.

11. Sen DK. Results of treatment of anisohypermetropic amblyopia without strabismus. Br J Ophtahlmol. 1982; 66:680–4.

12. Mintz-Hittner HA, Fernandez KM. Successful amblyopia therapy initiated after age 7 years. Arch Ophthalmol. 2000; 118:1535–41.

13. Roh GH, Cho YA. Compliance of patching therapy for amblyopia. J Korean Ophthalmol Soc. 1993; 34:1171–7.

14. Woodruff G, Hiscox F, Thompson JR, Smith LK. Factors affecting the outcome of children treated for amblyopia. Eye. 1994; 8:627–31.

15. Kaye SB, Chen SI, Price G. . Combined optical and atropine penalization for the treatment of strabismic and anisometropic amblyopia. J AAPOS. 2002; 6:289–93.

16. Kim BJ, Moon CS, Chang YH. . The amblyopia and strabismus accompanied with anisometropia. J Korean Ophthalmol Soc. 2007; 48:411–7.

17. Copps LA. Vision in anisometropia. Am J Ophthalmol. 1944; 27:641–4.

18. Hussein MA, Coats DK, Muthialu A. . Risk factors for treatment failure of anisometropic amblyopia. J AAPOS. 2004; 8:429–34.

19. The Pediatric Eye Disease Investigator Group. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology. 2003; 110:2075–87.

20. Rho SS, Yang HS, Chang YH. . The effect on outcome of amblyopia treatment in children with anisometropic amblyopia. J Korean Ophthalmol Soc. 2007; 48:535–40.

21. Longville D, Gnanaraj L. Does compliance with amblyopia manage improve following supervised occlusion treatment? Eur J Ophthalmol. 2007; 17:823–7.

22. Beardsell R, Clarke S, Hill M. Outcome of occlusion treatment for amblyopia. J Pediatr Ophthalmol Strabismus. 1999; 36:19–24.

23. Park SC, Lee KH, Kim JR. Clinical approach for visual achievement in amblyopia treatment. J Korean Ophthalmol Soc. 1991; 32:802–8.

24. Flynn JT, Schiffman J, Feuer W, Corona A. The therapy of amblyopia: an analysis of the results of amblyopia therapy utilizing the pooled data of published studies. Trans Am Ophthalmol Soc. 1998; 96:431–53.

25. Moon CS, Jin YH. Timing of amblyopia therapy in pure anisometropic amblyopia. J Korean Ophthalmol Soc. 1998; 39 :185-92.

26. Patwardhan NA. Is age relevant for the success of treatment of anisometropic amblyopia? Indian J Ophthalmol. 2007; 55:469–470.

27. Wu C, Hunter DG. Amblyopia: diagnostic and therapeutic options. Am J Ophthalmol. 2006; 141:175–84.

28. The Pediatric Eye Disease Investigator Group. A randomized pilot study of near activities versus non‐ near activities during patching therapy for amblyopia. J AAPOS. 2005; 9:129–36.